Congenital Adrenal Hyperplasia and the COVID-19 Pandemic:  The Calm before the Storm

Aida Al-Jabri

Abstract

Congenital Adrenal Hyperplasia and the COVID-19 Pandemic: The Calm before the Storm

Congenital Adrenal Hyperplasia (CAH) is considered one of the most frequent autosomal recessive disorders in humans. It is a quite higher incidence in Saudi Arabia than other countries, estimated by one in 5,000 live births to one in 6400. This disease treated with lifelong cortisone (different types) and recommends increasing the hydrocortisone dose, according to the general sick day rules. The new recommended medication to treat COVID-19 patients is Dexamethasone, which is the most potent form of cortisone and it is glucocorticoid effect higher than hydrocortisone by 25 times. Till the date of write this paper, there is no published case of CAH affected with COVID-19 infection, the reason behind it is not clear but could because they are already on cortisone management.

Author(s):

Aida Al-Jabri*

Abstract | Full-Text | PDF

Share this